Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Jost

Showing results (351-360 of 384) with videos related to

Pageof 39
Sort By:
NPJ Parkinson'S Disease|October 14, 2022
Disentangling nigral and putaminal contribution to motor impairment and levodopa response in Parkinson's diseaseNils Schröter, Michel Rijntjes, Horst Urbach, et al.
PM & R : the Journal of Injury, Function, and Rehabilitation|November 5, 2020
Long-Term Observational Results from the ASPIRE Study: OnabotulinumtoxinA Treatment for Adult Lower Limb SpasticityAlberto Esquenazi, Ganesh Bavikatte, Daniel S Bandari, et al.
International Journal of Rehabilitation Research. Internationale Zeitschrift Fur Rehabilitationsforschung. Revue Internationale De Recherches De Readaptation|February 16, 2010
The profile of patients and current practice of treatment of upper limb muscle spasticity with botulinum toxin type A: an international surveyAbdel Magid Bakheit, Benjamin Zakine, Pascal Maisonobe, et al.
Journal of Neural Transmission (Vienna, Austria : 1996)|April 11, 2025
Levodopa treatment: impacts and mechanisms throughout Parkinson's disease progressionPeter Riederer, Sabrina Strobel, Toshiharu Nagatsu, et al.
PM & R : the Journal of Injury, Function, and Rehabilitation|January 19, 2020
Individualized OnabotulinumtoxinA Treatment for Upper Limb Spasticity Resulted in High Clinician- and Patient-Reported Satisfaction: Long-Term Observational Results from the ASPIRE StudyGerard E Francisco, Wolfgang H Jost, Ganesh Bavikatte, et al.
Der Nervenarzt|November 27, 2012
[Therapy and care of patients with chronic migraine: expert recommendations of the German Migraine and Headache Society/German Society for Neurology as well as the Austrian Headache Society/Swiss Headache Society]A Straube, C Gaul, S Förderreuther, et al.
Movement Disorders Clinical Practice|February 4, 2025
Localization Matters: Impacts of PEG-J Localization in Intestinal Levodopa Therapy for Parkinson's DiseasePhilipp Klocke, Moritz A Loeffler, Idil Cebi, et al.
BMC Cancer|December 3, 2014
Quantitative assessment of the asphericity of pretherapeutic FDG uptake as an independent predictor of outcome in NSCLCIvayla Apostolova, Julian Rogasch, Ralph Buchert, et al.
Parkinsonism & Related Disorders|December 4, 2019
Long-term incobotulinumtoxinA treatment for chronic sialorrhea: Efficacy and safety over 64 weeksWolfgang H Jost, Andrzej Friedman, Olaf Michel, et al.
Neurology|March 29, 2019
SIAXI: Placebo-controlled, randomized, double-blind study of incobotulinumtoxinA for sialorrheaWolfgang H Jost, Andrzej Friedman, Olaf Michel, et al.
Pageof 39

Showing results (351-360 of 384) with videos related to

Sort By:
Pageof 39
NPJ Parkinson'S Disease|October 14, 2022
Disentangling nigral and putaminal contribution to motor impairment and levodopa response in Parkinson's diseaseNils Schröter, Michel Rijntjes, Horst Urbach, et al.
PM & R : the Journal of Injury, Function, and Rehabilitation|November 5, 2020
Long-Term Observational Results from the ASPIRE Study: OnabotulinumtoxinA Treatment for Adult Lower Limb SpasticityAlberto Esquenazi, Ganesh Bavikatte, Daniel S Bandari, et al.
International Journal of Rehabilitation Research. Internationale Zeitschrift Fur Rehabilitationsforschung. Revue Internationale De Recherches De Readaptation|February 16, 2010
The profile of patients and current practice of treatment of upper limb muscle spasticity with botulinum toxin type A: an international surveyAbdel Magid Bakheit, Benjamin Zakine, Pascal Maisonobe, et al.
Journal of Neural Transmission (Vienna, Austria : 1996)|April 11, 2025
Levodopa treatment: impacts and mechanisms throughout Parkinson's disease progressionPeter Riederer, Sabrina Strobel, Toshiharu Nagatsu, et al.
PM & R : the Journal of Injury, Function, and Rehabilitation|January 19, 2020
Individualized OnabotulinumtoxinA Treatment for Upper Limb Spasticity Resulted in High Clinician- and Patient-Reported Satisfaction: Long-Term Observational Results from the ASPIRE StudyGerard E Francisco, Wolfgang H Jost, Ganesh Bavikatte, et al.
Der Nervenarzt|November 27, 2012
[Therapy and care of patients with chronic migraine: expert recommendations of the German Migraine and Headache Society/German Society for Neurology as well as the Austrian Headache Society/Swiss Headache Society]A Straube, C Gaul, S Förderreuther, et al.
Movement Disorders Clinical Practice|February 4, 2025
Localization Matters: Impacts of PEG-J Localization in Intestinal Levodopa Therapy for Parkinson's DiseasePhilipp Klocke, Moritz A Loeffler, Idil Cebi, et al.
BMC Cancer|December 3, 2014
Quantitative assessment of the asphericity of pretherapeutic FDG uptake as an independent predictor of outcome in NSCLCIvayla Apostolova, Julian Rogasch, Ralph Buchert, et al.
Parkinsonism & Related Disorders|December 4, 2019
Long-term incobotulinumtoxinA treatment for chronic sialorrhea: Efficacy and safety over 64 weeksWolfgang H Jost, Andrzej Friedman, Olaf Michel, et al.
Neurology|March 29, 2019
SIAXI: Placebo-controlled, randomized, double-blind study of incobotulinumtoxinA for sialorrheaWolfgang H Jost, Andrzej Friedman, Olaf Michel, et al.
Pageof 39